Mineralys Therapeutics (MLYS) drew fresh attention after presenting Phase 3 lorundrostat data at ASN Kidney Week 2026, highlighting blood pressure and albuminuria reductions in patients with chronic ...
Source LinkMineralys Therapeutics (MLYS) drew fresh attention after presenting Phase 3 lorundrostat data at ASN Kidney Week 2026, highlighting blood pressure and albuminuria reductions in patients with chronic ...
Source Link
Comments